Meta-analysis of efficacy of Ligustrazine Hydrochloride Injection in the treatment of chronic obstructive pulmonary diseases
Objective To systematically evaluate the therapeutic efficacy of Ligustrazine Hydrochloride Injection in the treatment of chronic obstructive pulmonary diseases(COPD).Methods Randomized controlled trials(RCTs)about COPD were retrieved from CNKI,CBM,Wanfang,VIP databases,PubMed,EMBase,Web of Science,and Cochrane Library,of which the data were searched from inception to March 2023.The test group was treated with conventional Western medicine and Ligustrazine Hydrochloride Injection,and the control group was treated with conventional Western medicine treatment.After screening and extracting data,two independent reviewers critically appraised all included studies according to the cochrane systematic review method,and then used Revman 5.3 Software and Stata/MP 14.1 for Meta-analysis.Results A total of 22 RCTs and 1 822 patients were included after evaluating and screening the selected articles.The total clinical efficacy of the experimental group was significantly higher than that in the control group[RR(95％CI)=1.26(1.18,1.24),P＜0.001].The forced expiratory volume in one second(FEV1)was significantly improved compared to the control group[MD(95％CI)=0.34(0.17,0.51),P＜0.001].Forced vital capacity(FVC)was significantly larger than the control group[MD(95％CI)=0.38(0.16,0.60),P＜0.001].FEV1/FVC was significantly improved compared to the control group[MD(95％CI)=8.06(5.27,10.85),P＜0.01].PaO2 was significantly improved compared to the control group[MD(95％CI)=6.77(4.72,8.83),P＜0.001].PaCO2 was significantly lower than control group[MD(95％CI)=-7.84(-9.49,-6.20),P＜0.001].Fibrinogen(FIB)was significantly lower than the control group[MD(95％CI)=-1.04(-1.54,-0.53),P＜0.001].Tumour necrosis factor-α(TNF-α)was significantly lower than the control group[MD(95％CI)=-2.77(-3.24,-2.30),P＜0.001].Conclusion Based on the evidence,Ligustrazine Hydrochloride Injection combined with conventional Western medicine treatment can improve the clinical efficacy for patients with COPD,but this conclusion still needs to be further confirmed by more multicenter,large-sample studies.
万方数据
维普
